Concepedia

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

Thomas Hueso, Thomas Gastinne, Sylvain Garciaz, Emmanuelle Tchernonog, Caroline Delette, Olivier Casasnovas, Éric Durot, Roch Houot, Benoît Tessoulin, Olivier Tournilhac,

Bone Marrow Transplantation · 2020 · 24 citations · 29 references

DOIFull text

Open access

Concepts

References

29

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

, , +17

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

, , +6

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Eva Hoster, Martin Dreyling, Christian Gisselbrecht et al. · Blood · 2007 · 971 citations

, , +11

Competing risk analysis using R: an easy guide for clinicians

Luca Scrucca, Annalisa Santucci, Franco Aversa · Bone Marrow Transplantation · 2007 · 703 citations

, , +5

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood · 2014 · 638 citations · Full text

, , +3